Hanssen Pharmaceutical (03692.HK): HS-10582 tablets have received the clinical trial approval notification from the National Medical Products Administration.

Zhito Finance APP news, Hansen Pharmaceutical (03692.HK) announced that its self-developed Class 1 new drug HS-10582 tablets have been granted a clinical trial approval notice by the National Medical Products Administration (NMPA) of China, intended for conducting clinical trials for "the treatment of adult primary hypercholesterolemia and mixed dyslipidemia."